-
Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares
-
Alder BioPharma (ALDR) Prices 11.3M Share Common Offering at $11.50/Sh
-
Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock
-
Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock
-
Alder BioPharma (ALDR) to Offer Up to $105M in Common Stock and Concurrent Private Placement
-
Alder BioPharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
-
Alder BioPharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
-
Alder Biopharm (ALDR) PT Lowered to $25 at RBC Capital
-
Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
-
Alder Biopharm (ALDR) PT Raised to $27 at RBC Capital; 'All On Track For 1Q19 Epti BLA Filing'
-
RBC Positive on Biogen (BIIB) Karp Hire Amid Partnerships/M&A Potential
-
RBC Sees Positive Read-Through to Alder Biopharm (ALDR) from Allergan, Biogen Developments
-
Alder BioPharma (ALDR) Has Positive Read-Through from Eli Lilly's Cluster Headache Data - RBC
-
Alder Biopharm (ALDR) PT Lowered to $24 at RBC Capital
-
Biogen (BIIB) Missed Out on AveXis (AVXS) But Well-Positioned for Substantial Acquisition - RBC
-
Alder BioPharmaceuticals® to Present at Two Upcoming February Investor Conferences
-
Alder BioPharmaceuticals® to Present at Two Upcoming February Investor Conferences
-
RBC Capital Starts Alder Biopharm (ALDR) at Outperform
-
Notable Analyst Rating Changes 6/24: (RCL) (EA) (MRGE) Upgraded; (C) (GM) (FTNT) Downgraded

